8-K: Merit Medical Exceeds Q4, FY25 Targets; Strong 2026 Outlook

Merit Medical Systems, Inc. reported better-than-expected fourth quarter and full-year 2025 financial results, alongside optimistic guidance for fiscal year 2026.

Summary

• Merit Medical Systems, Inc. announced strong financial results for the fourth quarter and full fiscal year ended December 31, 2025.
• Fourth quarter 2025 reported revenue increased 11% to $393.9 million, with GAAP EPS up 37% to $0.63 and Non-GAAP EPS up 12% to $1.04.
• Full fiscal year 2025 reported revenue grew 12% to $1.516 billion, with GAAP EPS up 5% to $2.13 and Non-GAAP EPS up 11% to $3.83.
• The company generated significant free cash flow of $74.0 million in Q4 2025 and $215.7 million for the full year 2025.
• Merit provided fiscal year 2026 guidance, projecting total revenue between $1.610 billion and $1.630 billion (6%-8% growth) and Non-GAAP EPS between $4.01 and $4.15 (5%-8% growth).

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong financial performance exceeding expectations and robust guidance for the upcoming fiscal year, indicating sustained operational strength and effective strategic execution.

Positives

• Fourth quarter 2025 reported revenue increased 11% to $393.9 million, exceeding expectations.
• Full fiscal year 2025 reported revenue grew 12% to $1.516 billion.
• GAAP operating margin improved to 13.8% in Q4 2025 (from 10.3% in Q4 2024) and to 12.2% for FY 2025 (from 11.5% in FY 2024).
• Non-GAAP operating margin saw a 130 basis-point improvement year-over-year for FY 2025, reaching 20.3%.
• GAAP EPS for Q4 2025 surged 37% to $0.63, and Non-GAAP EPS rose 12% to $1.04.
• Full year Non-GAAP EPS increased 11% to $3.83.
• Strong free cash flow generation of $74.0 million in Q4 2025 (up 13%) and $215.7 million for FY 2025 (up 16%).
• The company ended FY 2025 with $446.4 million in cash and cash equivalents and $697 million in available borrowing capacity.
• Positive fiscal year 2026 guidance for revenue (6%-8% growth) and Non-GAAP EPS (5%-8% growth), reflecting confidence in continued strong execution and profitability.

Negatives

• OEM product category reported revenue declined 15% to $48.085 million in the fourth quarter of 2025 compared to $56.314 million in the prior year period.

Risks

• Risks and uncertainties associated with executive succession planning activities and leadership transition.
• Trade policies or related actions implemented by the U.S. or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures.
• Integration of businesses or products acquired from third parties (C2 Acquisition, Biolife Merger, Cook Transaction, EGS Transaction) and the ability to achieve anticipated financial results and benefits.
• Effects of the 3.00% Senior Convertible Notes due 2029 on net income and earnings per share performance.
• Disruptions in supply chain, manufacturing or sterilization processes.
• U.S. and global political, economic, competitive, reimbursement and regulatory conditions.
• Modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies.
• Reduced availability of, and price increases associated with, components and other raw materials.
• Increases in transportation expenses.
• Potential inability to successfully manage growth through acquisitions generally, including integrating acquired operations or commercializing technology.
• Fluctuations in interest or foreign currency exchange rates and inflation.
• Cybersecurity events.
• Government scrutiny and regulation of the medical device industry.
• Difficulties relating to development, testing and regulatory approval, clearance and maintenance of products.
• The safety, efficacy and patient and physician adoption of products.
• Ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to products.
• Litigation and other legal proceedings affecting Merit.
• Failure to comply with U.S. and foreign laws and regulations.
• Restrictions on liquidity or business operations resulting from debt agreements.
• Infringement of technology or the assertion that technology infringes the rights of other parties.
• Product recalls and product liability claims.
• Potential for significant adverse changes in governing regulations.
• Divestiture of the DualCap anti-microbial cap product line in February 2026.
• Changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities.
• Termination of relationships with suppliers, or failure of such suppliers to perform.
• Development of new products and technology that could render existing or future products obsolete.
• Market acceptance of new products.
• Failure to comply with applicable environmental laws.
• Changes in key personnel.
• Labor shortages and increases in labor costs.
• Price and product competition.
• Extreme weather events.
• Geopolitical events.

Future Outlook

Merit Medical Systems, Inc. anticipates total revenue for fiscal year 2026 to be between $1.610 billion and $1.630 billion, representing a 6% to 8% increase year-over-year on a reported basis, or 5% to 7% on a constant currency basis. Non-GAAP earnings per share are projected to be in the range of $4.01 to $4.15, reflecting a 5% to 8% increase year-over-year. The company expects continued strong execution, stable constant currency growth, improving profitability, and solid free cash flow generation.

Management Comments

• Merit delivered better-than-expected revenue and financial results in the fourth quarter.
• The fourth quarter capped off an impressive year of operating and financial performance in 2025, with 6.8% organic, constant currency revenue growth, a 130 basis-point improvement year-over-year in non-GAAP operating margin, and strong free cash flow of more than $215 million, a 16% increase year-over-year.
• The introduction of 2026 revenue and non-GAAP earnings per share guidance reflects confidence in the team's ability to deliver continued strong execution, stable constant currency growth, improving profitability, and solid free cash flow generation.
• The team remains laser-focused on delivering the final year of the Continued Growth Initiatives Program and its related financial targets for the three-year period ending December 31, 2026.

Industry Context

StockSavvy.ai notes that Merit Medical's strong performance in medical device sectors like interventional cardiology and endoscopy aligns with increasing demand for minimally invasive procedures and an aging global population. The company's strategic acquisitions, such as C2 CryoBalloon and Biolife, and its focus on improving profitability and generating robust free cash flow, suggest a proactive approach to market leadership and operational efficiency within a competitive healthcare technology landscape.

Corporate Governance

Legal Proceedings

• The company incurs costs to comply with its corporate integrity agreement with the U.S. Department of Justice.
• Litigation and other legal proceedings are identified as a potential risk factor affecting the company.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, robust free cash flow, and optimistic future guidance, potentially leading to increased share value.
• Employees: Continued growth and strategic initiatives suggest stability and potential opportunities, though corporate restructuring and employee termination benefits were noted as non-GAAP adjustments.
• Customers: Benefit from continued product development and integration of acquired technologies (e.g., C2 CryoBalloon, Biolife products), enhancing product offerings in various medical fields.
• Suppliers: Continued growth and manufacturing activities imply ongoing demand for components and raw materials, though risks related to supplier performance and availability are noted.

Next Steps

• Conduct a conference call on February 24, 2026, to discuss operating and financial results and provide an operational update.
• Continue to focus on delivering the final year of the 'Continued Growth Initiatives Program' and its related financial targets for the three-year period ending December 31, 2026.

Key Dates

Recommendation

Merit Medical Systems, Inc. has demonstrated exceptional financial performance in Q4 and FY 2025, exceeding expectations with significant growth in revenue, operating margins, and EPS. The robust free cash flow generation and strong balance sheet provide a solid foundation. Furthermore, the optimistic guidance for FY 2026, coupled with management's confidence in continued execution and profitability, signals sustained positive momentum. The strategic integration of recent acquisitions is expected to contribute to future growth. While some risks exist, the overall outlook is highly favorable, making it a strong buy for investors seeking growth in the medical technology sector.

Keywords

Medical devices, Healthcare technology, Interventional procedures, Diagnostic procedures, Therapeutic procedures, Cardiology, Radiology, Oncology, Critical care, Endoscopy, Financial results, Earnings, Revenue, EPS, Free cash flow, Guidance, Acquisitions, Corporate governance